Slide 1: FY 2023 Earnings Call
FY 2023 Earnings Call March 12, 2024
Slide 2: Presenters
Jerrell Shelton Robert Stefanovich CEO - Cryoport CFO, SVP - Cryoport Mark Sawicki, Ph.D. Thomas Heinzen Chief Scientific Officer – Cryoport VP Investor Relations and and CEO - Cryoport Systems Corporate Development - Cryoport
Slide 3: Forward Looking Statements
Forward Looking Statements Statements in this press release which are not purely historical, including statements regarding the Company's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of t
Slide 4: Cryoport, Inc. Organization
Cryoport, Inc. Organization (NASDAQ: CYRX) © 2024 CRYOPORT, INC. 4
Slide 5: Cryoport - Snapshot
Cryoport - Snapshot Performance Driven Global Platform (2) over 50 Facilities Globally $233.3 MM $242- $252 MM $456.8 MM in 17 Countries FY 2023 Revenue FY 2024 Revenue Cash & Short-Term Guidance investments C> Supply Chain Leader Over 3,000+ Global Clients 14 +33% YoY 675 1,100+ Employees Commerc
Slide 6: Global CGT Market is Projected to Reach $80 Billion by 2029
Global CGT Market is Projected to Reach $80 Billion by 2029 CGT market value by indication 2022-29 The cell and gene therapy market is expected to grow at a high CAGR of 51.6% Oncology is expected to command 44% of the CGT market in 2029 $90 $80 Billions so 2022 2023 2024 2025 2026 Oncology ™ Metabo
Slide 7: Growing Cell & Gene Therapy Pipeline
Growing Cell & Gene Therapy Pipeline ✓675 clinical trials (net) in aggregate Clinical Trials Supported by Trial Phase ✓82 Phase III trials in the Americas, EMEA and APAC as of 12/31/23 Increased by 21 trials (net) over FY 2022 Phase III 12% Phase I 42% Phase II 46% Phase I Phase II Phase III Source:
Slide 8: Clinical Trial Update
Clinical Trial Update 946 Industry Clinical Trials – Cryoport Supporting 675 Trials or 71% © 2024 CRYOPORT, INC. 8
Slide 9: CGT Clinical Trials by Phase and Region
CGT Clinical Trials by Phase and Region © 2024 CRYOPORT, INC. 9
Slide 10: Biopharma: IPO & Secondary Funding
Biopharma: IPO & Secondary Funding © 2024 CRYOPORT, INC. 10
Slide 11: Cryoport Revenue Drivers
Cryoport Revenue Drivers Services revenue 62% of total revenue in FY 2023 FY 2022 Revenue FY 2023 Revenue Product Product 44% 38% Services Services 56% 62% © 2024 CRYOPORT, INC. 11
Slide 12: A Unified Network Supporting the Life Sciences
A Unified Network Supporting the Life Sciences 17 countries > 50 locations US IE Brentwood, Tennessee Dublin Irvine, California PL Morris Plains, New Jersey Warsaw Houston, Texas Ball Ground, Georgia PH New Prague, Minnesota Manila Valley Stream, New York KR Huntington Beach, California Seoul Chicag
Slide 13: Cryoport BioServices
Cryoport BioServices © 2024 CRYOPORT, INC. 13
Slide 14: Cryoport Elite Ultra Cold Dry Ice Shippers
Cryoport Elite™ Ultra Cold Dry Ice Shippers Why the Cryoport Elite™ Shippers? ° Proprietary and scientifically engineered to provide increased security and certainty for irreplaceable commodities ° Delivers superior performance with hold times that significantly exceed industry standards (140+ hours
Slide 15: Accelerating Cell Therapy Programs
Accelerating Cell Therapy Programs Strategic 3rd Party Partnerships Leukapheresis Storage & Cryopreservation Collection Distribution Integricell - Standardization and Integration to Chain of Compliance® © 2024 CRYOPORT, INC. 15
Slide 16: CRYOPDP
CRYOPDP We provide customized solutions tailored to meet In one page our customers’ needs. With an extensive offer from Focused on Life Science and packaging, to transport and Healthcare added-value solutions 99,97% Service Quality Backed by a team of experienced Countries reached professionals in t
Slide 17: MVE At A Glance
MVE At A Glance Our global operations: Over 60 years of setting ● Ball Ground, GA - USA (Headquarters) the standard for ● New Prague, MN - USA ● Manheim, Germany cryogenic storage ● Chengdu, China The global leading manufacturer of cryogenic freezers and dewars for life sciences, animal health, and
Slide 18: Carbon Footprint Measurement Results
Carbon Footprint Measurement Results 2021 Total Emissions 2022 Total Emissions Scope Item Emission Source (MT CO2-e) (MT CO2-e) Scope 1 Stationary Combustion 447 405 Scope 1 Mobile Sources 2,016 717 Scope 1 Refrigerants 150 230 Scope 2 Purchased Electricity (Location-Based) 6,988 4,879 Scope 2 Purch
Slide 19: Multi-Year ESG Impact Outcomes
Multi-Year ESG Impact Outcomes Pathway Impacts 2020 Outcomes 2021 Outcomes 2022 Outcomes 2023 Outcomes Cryoport Access for 9,586 13,477 12,572 19,665 Systems Patients additional patients were able additional patients were able additional patients were able additional patients were able to receive th
Slide 20: Revenue by Market
Revenue by Market © 2024 CRYOPORT, INC. 20
Slide 21: Balance Sheets
Balance Sheets $456.8MM © 2024 CRYOPORT, INC. 21
Slide 22: Statement of Operations
Statement of Operations © 2024 CRYOPORT, INC. 22
Slide 23: Adjusted EBITDA
Adjusted EBITDA © 2024 CRYOPORT, INC. 23
Slide 24: FY 2024 Revenue Guidance
FY 2024 Revenue Guidance © 2024 CRYOPORT, INC. 24
Slide 25: Upcoming Investor Conferences
Upcoming Investor Conferences Host Conference Date Location 36th Annual Investment Roth March 17-19, 2024 Dana Point, CA Conference Life Sciences and Medtech KeyBanc March 19-20, 2024 Virtual Investor Forum 23rd Annual Healthcare Needham April 8-11, 2024 Virtual Conference Bank of America Global Hea